million and $
2,669
million as of December 31, 2024 and 2023, respectively. In order to maintain appropriate regulatory capital levels, in the quarter ended June 30, 2023, we made the previously reported non-cash capital contributions in the form of intercompany loan forgiveness of $
1,797
million; no incremental contributions from GE Aerospace were required in 2024. For further information about factors that are relevant to the estimate of total losses for borrower litigation at Bank BPH, see Note 24. Future changes or adverse developments could increase our estimate of total losses and potentially require future cash contributions to Bank BPH.
The Bank BPH financing receivable portfolio is recorded at the lower of cost or fair value, less cost to sell, which reflects market yields and estimates with respect to ongoing borrower litigation. At December 31, 2024, the total portfolio had
no
carrying value, net of a valuation allowance. Earnings (loss) related to ongoing borrower litigation included
zero
, $
1,189
million and $
720
million in pre-tax charges for the years ended December 31, 2024, 2023 and 2022, respectively.
48
2024 FORM 10-K
The tax benefit for the year ended December 31, 2023 for GE HealthCare relates to retroactive 2023 Internal Revenue Service (IRS) guidance concerning foreign tax credits and accounting method changes and completion of the 2022 U.S. federal tax return, as well as net tax benefit resulting from preparatory steps for the spin-off.
2024 FORM 10-K
49
(a) Included $
1,324
million and $
1,391
million of cash, cash equivalents and restricted cash related to Bank BPH as of December 31, 2024 and 2023, respectively.
(b) Included $
1,594
million and $
1,963
million of valuation allowances against financing receivables held for sale, of which $
1,517
million and $
1,712
million related to estimated borrower litigation losses, and $
944
million and $
957
million in All other liabilities, related to estimated borrower litigation losses for Bank BPHâ€™s foreign currency-denominated mortgage portfolio, as of December 31, 2024 and 2023, respectively. Accordingly, total estimated losses related to borrower litigation were $
2,461
million and $
2,669
million as of December 31, 2024 and 2023, respectively. As a result of the settlement program, the valuation allowance completely offsets the financing receivables balance as of December 31, 2024.
(c) Included $
102
million and $
46,233
million of assets and $
148
million and $
38,021
million of liabilities for GE Vernova as of December 31, 2024 and 2023, respectively.
NOTE 3.
INVESTMENT SECURITIES.
The majority of our investment securities are held within our run-off insurance operations and are classified as non-current as they support the long-duration insurance liabilities and include debt securities all classified as available-for-sale, substantially all of which are investment-grade.
We sold our remaining equity shares in GE HealthCare during the fourth quarter of 2024. Our senior